Resonance Specialties to Acquire Kaygee Laboratories' Mandideep Unit for ₹29.98 Crore

Q1 FY27 Standalone Results YoY: Revenue at 32.6 Cr vs 21.3 Cr, up 53.2%. EBITDA at 8.0 Cr vs 2.8 Cr, up 188.0%. EBITDA Margin at 24.6% vs 13.1%, expansion of 1150bps. PAT at 5.7 Cr vs 1.6 Cr, up 252.3%. Outside India revenue was the key driver at 21.9 Cr vs 10.7 Cr, up 118.3%, while India revenue declined 12.2% to 9.3 Cr. Board approved the proposed acquisition of a WHO-approved Mandideep manufacturing facility from promoter-group company Kaygee Laboratories for 29.98 Cr on a slump-sale basis, subject to shareholder approval, to secure API and chemical-intermediate production and reduce outsourcing costs.